UPDATE: Barclays Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Equalweight

November 29, 2016 6:40 AM EST
Get Alerts BMRN Hot Sheet
Price: $87.16 +2.29%

Rating Summary:
    20 Buy, 6 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade BMRN Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
(Updated - November 29, 2016 8:17 AM EST)

Barclays downgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Overweight to Equalweight with a price target of $105.00 (from $125.00). Analyst Geoff Meacham highlighted moderating growth and an overall lack of catalysts in 2017.

For an analyst ratings summary and ratings history on BioMarin Pharmaceutical Inc. click here. For more ratings news on BioMarin Pharmaceutical Inc. click here.

Shares of BioMarin Pharmaceutical Inc. closed at $88.36 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Downgrades

Related Entities

Barclays

Add Your Comment